A fixed-dose combination of a cytoprotective agent (Sucralfate) and a potent local anesthetic (Oxetacaine) used for the symptomatic relief and healing of acid-peptic disorders. Sucralfate forms a protective barrier over ulcers/erosions, while Oxetacaine provides rapid, topical analgesia by inhibiting nerve conduction at the site of application.
Adult: 1 tablet (500mg + 10mg) four times daily: one hour before meals and at bedtime. For GERD, often taken 1 hour after meals and at bedtime. Maximum: 4 tablets/day.
Note: Tablet must be taken on an empty stomach (at least 1 hour before or 2 hours after food). Swallow whole with a full glass of water. Do not crush or chew. Maintain at least a 2-hour gap between this medication and other drugs (especially antacids, PPIs, H2 blockers, tetracyclines, fluoroquinolones) as it interferes with their absorption.
Sucralfate: In the acidic environment of the stomach, it polymerizes to form a viscous, adhesive gel-like substance that binds selectively to ulcer craters and erosions, creating a physical barrier against acid, pepsin, and bile salts. It also stimulates local prostaglandin synthesis, bicarbonate secretion, and binds epidermal growth factor (EGF), concentrating it at the ulcer site to promote healing. Oxetacaine: A surface anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx required for the initiation and conduction of nerve impulses, thereby providing rapid topical analgesia to the esophageal and gastric mucosa.
Pregnancy: Category B. Sucralfate is not absorbed systemically; Oxetacaine absorption is minimal. Use only if clearly needed. Considered relatively safe for short-term use in pregnancy for severe gastritis.
Driving: Oxetacaine may rarely cause dizziness. Patients should not drive or operate machinery if they experience dizziness.
| Antacids (Aluminum/Magnesium hydroxide) | Reduced efficacy of Sucralfate (alters gastric pH) | Major |
| Proton Pump Inhibitors (Omeprazole, Pantoprazole) | PPIs may reduce Sucralfate efficacy (need acidic pH). Administer Sucralfate 2 hours before PPI. | Moderate |
| H2 Blockers (Ranitidine, Famotidine) | Similar to PPIs. Stagger administration. | Moderate |
| Tetracycline antibiotics (Doxycycline) | Markedly reduced absorption of tetracycline. | Major |
| Fluoroquinolones (Ciprofloxacin, Levofloxacin) | Reduced absorption of fluoroquinolone, leading to therapeutic failure. | Major |
| Digoxin | Reduced absorption of Digoxin. | Moderate |
| Phenytoin | Reduced absorption of Phenytoin. | Moderate |
| Thyroxine (Levothyroxine) | Reduced absorption of Thyroxine. | Major |
| Warfarin | Potential reduction in Warfarin absorption; monitor INR. | Moderate |
| Ketoconazole | Reduced absorption of Ketoconazole. | Major |
Same composition (Sucralfate (500mg) + Oxetacaine (10mg)), different brands: